Adaptive clinical trial design.

In recent years, the use of adaptive design methods in clinical trials based on accumulated data at interim has received much attention because of its flexibility and efficiency in pharmaceutical/clinical development. In practice, adaptive design may provide the investigators a second chance to modify or redesign the trial while the study is still ongoing. However, it is a concern that a shift in target patient population may occur after significant adaptations are made. In addition, the overall type I error rate may not be preserved. Moreover, the results may not be reliable and hence are difficult to interpret. As indicated by the US Food and Drug Administration draft guidance on adaptive design clinical trials, the adaptive design has to be a prospectively planned opportunity and should be based on information collected within the study, with or without formal statistical hypothesis testing. This article reviews the relative advantages, limitations, and feasibility of commonly considered adaptive designs in clinical trials. Statistical concerns when implementing adaptive designs are also discussed.

[1]  Michael Krams,et al.  Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .

[2]  Jeff Maca,et al.  Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples , 2006 .

[3]  Richard Simon,et al.  Two-stage selection and testing designs for comparative clinical trials , 1988 .

[4]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[5]  D. Berry,et al.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.

[6]  A. Gould,et al.  Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance , 1992 .

[7]  Sue-Jane Wang,et al.  Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.

[8]  Elizabeth Garrett-Mayer,et al.  The continual reassessment method for dose-finding studies: a tutorial , 2006, Clinical trials.

[9]  A L Gould,et al.  Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. , 1992, Statistics in medicine.

[10]  Sue-Jane Wang,et al.  Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset , 2007, Pharmaceutical statistics.

[11]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[12]  I. White.  Estimating treatment effects in randomized trials with treatment switching , 2006, Statistics in medicine.

[13]  Shein-Chung Chow,et al.  Benefits, challenges and obstacles of adaptive clinical trial designs , 2011, Orphanet journal of rare diseases.

[14]  Boris Freidlin,et al.  Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.

[15]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.

[16]  P F Thall,et al.  A two-stage design for choosing among several experimental treatments and a control in clinical trials. , 1989, Biometrics.

[17]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[18]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[19]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[20]  Janet Woodcock,et al.  FDA introductory comments: clinical studies design and evaluation issues , 2005, Clinical trials.

[21]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[22]  M. Mugford,et al.  Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. , 2008, The Cochrane database of systematic reviews.

[23]  M. Christian,et al.  Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Chow,et al.  Statistical Consideration of Adaptive Methods in Clinical Development , 2005, Journal of biopharmaceutical statistics.

[25]  S. Chow,et al.  Statistical inference for cancer trials with treatment switching , 2005, Statistics in medicine.

[26]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[27]  A. Gould.  Planning and revising the sample size for a trial. , 1995, Statistics in Medicine.

[28]  J. Cui,et al.  Nonparametric Estimation of a Delay Distribution Based on Left‐Censored and Right‐Truncated Data , 1999, Biometrics.

[29]  Aloka G Chakravarty,et al.  Regulatory Aspects in Using Surrogate Markers in Clinical Trials , 2005, The Evaluation of Surrogate Endpoints.

[30]  Allan R Sampson,et al.  Drop‐the‐Losers Design: Normal Case , 2005, Biometrical journal. Biometrische Zeitschrift.

[31]  Annpey Pong.  Guest-Editor's Note: “Statistical Issues in Adaptive Design Methods in Clinical Trials” , 2007 .

[32]  Tze Leung Lai,et al.  Adaptive trial designs. , 2012, Annual review of pharmacology and toxicology.

[33]  Michael A Proschan,et al.  Two-Stage Sample Size Re-Estimation Based on a Nuisance Parameter: A Review , 2005, Journal of biopharmaceutical statistics.

[34]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[35]  A. Cohen,et al.  Exact Tests That Recover Interblock Information in Balanced Incomplete Blocks Designs , 1989 .

[36]  Mark Chang,et al.  Adaptive Design Methods in Clinical Trials , 2006 .

[37]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[38]  Richard Simon,et al.  Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Alexia Iasonos,et al.  A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies , 2008, Clinical trials.

[40]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[41]  R. G. Cornell,et al.  Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. , 1985, Pediatrics.

[42]  S. Chow,et al.  On the Independence of Data Monitoring Committee in Adaptive Design Clinical Trials , 2012, Journal of biopharmaceutical statistics.

[43]  Boris Freidlin,et al.  Biomarker-adaptive clinical trial designs. , 2010, Pharmacogenomics.

[44]  J. Whitehead,et al.  Estimating a treatment effect in survival studies in which patients switch treatment , 2002, Statistics in medicine.

[45]  Daniel J Sargent,et al.  Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.